Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders

@article{Scuderi2009CannabidiolIM,
  title={Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders},
  author={Caterina Scuderi and Daniele De Filippis and Teresa Iuvone and Angelo Blasio and Antonio Steardo and Giuseppe Esposito},
  journal={Phytotherapy Research},
  year={2009},
  volume={23}
}
Cannabidiol (CBD) is the main non‐psychotropic component of the glandular hairs of Cannabis sativa. It displays a plethora of actions including anticonvulsive, sedative, hypnotic, antipsychotic, antiinflammatory and neuroprotective properties. However, it is well established that CBD produces its biological effects without exerting significant intrinsic activity upon cannabinoid receptors. For this reason, CBD lacks the unwanted psychotropic effects characteristic of marijuana derivatives, so… 
Potential Effects of Cannabidiol as a Wake-Promoting Agent
TLDR
This review will provide experimental evidence regarding the potential role of CBD as a wake-inducing drug and investigate the pharmacological properties of CBD with significant findings.
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
TLDR
A narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.
Current application of cannabidiol (CBD) in the management and treatment of neurological disorders
TLDR
In the current review, the authors have shed light on the application of CBD in the management and treatment of various neurological disorders.
Cannabidiol, neuroprotection and neuropsychiatric disorders.
annabidiol , neuroprotection and neuropsychiatric disorders
TLDR
Cannabidiol attenuates brain damage associated with neurodegenerative and/or ischemic conditions, and has positive effects on attenuating psychotic-, anxiety and depressive-like behaviors.
Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review
TLDR
Cannabidiol has been reported to interact with anti-epileptic drugs, antidepressants, opioid analgesics, and THC, but surprisingly, it interacts with several other common medications, e.g. acetaminophen, and substances including alcohol.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 68 REFERENCES
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
TLDR
Hair samples were analysed to examine levels of Δ9-THC and CBD in 140 individuals and three clear groups emerged: ’THC only’, ‘THC+CBD’ and those with no cannabinoid in hair, which provides evidence of the divergent properties of cannabinoids.
The anticonvulsant activity of cannabidiol and cannabinol.
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
TLDR
This study aimed to investigate whether the properties of cannabidiol extend to CB1 receptors expressed in mouse brain and to human CB2 receptors that have been transfected into CHO cells.
The Cannabinoids as Potential Antiepileptics
TLDR
The anticonvulsant nature of cannabidiol suggests that it has a therapeutic potential in at least three of the four major types of epilepsy: grand mal, cortical focal, and complex partial seizures.
Open label evaluation of cannabidiol in dystonic movement disorders.
TLDR
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study and appears to have antidystonic and Parkinsonism-aggravating effects in humans.
Cannabidiol monotherapy for treatment-resistant schizophrenia
TLDR
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days.
Hypnoticlike effects of cannabidiol in the rat
  • J. Monti
  • Biology, Psychology
    Psychopharmacology
  • 2004
TLDR
Tolerance developed to all the effects of cannabidiol on the sleep-wakefulness cycle of male Wistar rats after once-daily injections of 40 mg/kg CBD for 15 days.
Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression
TLDR
The present study, performed in a mouse model of AD‐related neuroinflammation, was aimed at confirming in vivo the previously reported antiinflammatory properties of CBD.
...
1
2
3
4
5
...